Murray S, McLintock C, Lazure P, et al. Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study. Res Pract Thromb Haemost. 2019;3:626--638. 10.1002/rth2.12237

**Funding Information**

Funding for AXDEV Group to conduct this study came from ISTH education research funds.

EssentialsThis was a mixed‐methods study in 24 countries to identify areas where ISTH could support the thrombosis and hemostasis community.Diagnosis/testing needs identified included thrombosis risk, genetic testing, and von Willebrand disease (VWD).Treatment needs identified included anticoagulants, preventive treatments, and VWD.Research needs identified included enhanced collaboration and promotion of basic science research.

1. INTRODUCTION {#rth212237-sec-0007}
===============

Hemostatic disorders such as thrombosis and bleeding conditions occur when the process for normal hemostatic equilibrium is altered.[1](#rth212237-bib-0001){ref-type="ref"} Basic science research conducted on coagulation mechanisms has greatly improved scientific knowledge of the complex pathophysiology of coagulation disorders.[2](#rth212237-bib-0002){ref-type="ref"}, [3](#rth212237-bib-0003){ref-type="ref"}The past decade has seen significant advancements in technology used to study molecular and pathophysiologic processes in hemostatic disorders.[4](#rth212237-bib-0004){ref-type="ref"}

In the field of thrombosis and hemostasis (T&H), basic science and clinical research has led to considerable advancements in clinical therapies,[5](#rth212237-bib-0005){ref-type="ref"}, [6](#rth212237-bib-0006){ref-type="ref"}, [7](#rth212237-bib-0007){ref-type="ref"} including the development of long‐acting coagulation factors and gene therapy for patients with hemophilia,[8](#rth212237-bib-0008){ref-type="ref"} new approaches and agents for anticoagulation to prevent or treat thrombosis,[9](#rth212237-bib-0009){ref-type="ref"} and new insights into the connection between coagulation, inflammation, and immunity.[10](#rth212237-bib-0010){ref-type="ref"}

These advances have led to an increasingly complicated decision‐making process, reflected by the complex impact that hemostatic imbalance can have on the complement system, immunity, and inflammation and, therefore, the management of hemostatic disorders.[11](#rth212237-bib-0011){ref-type="ref"}, [12](#rth212237-bib-0012){ref-type="ref"} This situation is compounded, in some instances, where access to even basic laboratory testing and medications is limited,[13](#rth212237-bib-0013){ref-type="ref"} as are opportunities to access the latest scientific knowledge, tests, devices, or medications, compromising provision of optimal clinical care.[14](#rth212237-bib-0014){ref-type="ref"}

Given this rapidly evolving context, educational activities are needed to ensure optimal knowledge dissemination to T&H professionals. Specialty societies are in a position to provide support and educational offerings that facilitate access to appropriate resources and tools that enable the production of high‐quality, relevant, basic science and clinical research. However, there is currently a lack of research identifying the specific challenges faced by clinicians and researchers --- information that is necessary to develop impactful, evidence‐based solutions.

Though it is increasingly recognized that educational offerings must be designed on the basis of the learners' needs,[15](#rth212237-bib-0015){ref-type="ref"}, [16](#rth212237-bib-0016){ref-type="ref"} often these needs are presumed, rather than objectively determined. To better understand the needs of the T&H community, the International Society on Thrombosis and Haemostasis (ISTH) conducted a needs assessment of its membership and other professionals in the field. The study objective was to identify areas where the T&H community, including ISTH members, faced challenges and could benefit from the support of a specialty society.

2. METHODS {#rth212237-sec-0008}
==========

The ISTH enlisted AXDEV to carry out a mixed‐methods assessment of the needs of the T&H community. Participants were both members and nonmembers, whose professions included physicians, clinical researchers, basic science researchers, residents, fellows, doctoral and postdoctoral students, and industry representatives.

Collection of qualitative and quantitative data was done in 3 consecutive phases. Prior to the first data collection phase, a literature review was conducted to determine the areas of exploration and identify challenges faced by clinicians or researchers. These areas were discussed and refined with subject matter experts to inform the design of the interview guides.

The KSA (knowledge, skills, and attitude) model[17](#rth212237-bib-0017){ref-type="ref"} was used to structure the design of data collection tools. Behavioral and educational researchers in the field of health care (co‐authors SM, PL, and MP) executed the study design and data collection, while subject matter experts (co‐authors CM, SS, SMR, JHM, TR, and IP) provided scientific and clinical expertise in the field of T&H. Data were interpreted by both groups.

2.1. Phase 1: Individual interviews {#rth212237-sec-0009}
-----------------------------------

Individuals from 7 different professions and specialties participated in semistructured 45‐minute interviews. Interviews consisted of open‐ended questions described in Data S1, to prompt discussion and gain an in‐depth understanding of participants' perspectives on themes predetermined in the study design phase.[18](#rth212237-bib-0018){ref-type="ref"} Interviews were conducted in English by trained interviewers (including PL, MP, and SM), with questions adapted to the participants' occupation. The most substantive themes that emerged from the qualitative analysis were discussed with subject matter experts and used to inform the phase 2 online survey.

2.2. Phase 2: Online survey {#rth212237-sec-0010}
---------------------------

Survey questions were developed by educational researchers and reviewed by subject matter experts to ensure clinical relevance and validity. The survey aimed to validate the extent to which previously identified challenges or specific perspectives were represented in a larger sample of participants. Response scales and survey sections are described in Data S1. Survey items and examples of questions can be found in Tables 2 and 3. Eligible participants were categorized by their reported profession, and subsequent questions were adjusted accordingly. Surveys were deployed in English only, using vocabulary that is accessible to individuals with another first language. Phase 2 data were then analyzed and triangulated with qualitative data (phase 1) and literature review findings.

2.3. Phase 3: Discussion groups {#rth212237-sec-0011}
-------------------------------

Findings from phases 1 and 2 were presented during 90‐minute discussion groups at the ISTH 2017 Congress (July 8‐13, 2017). These groups included participants from various countries and diverse professions, and aimed to obtain insights as well as potential explanations for the identified challenges. The most substantive themes that emerged from these discussion groups were used in the final triangulation of data, leading to the key findings (see analysis section).

2.4. Recruitment and inclusion criteria {#rth212237-sec-0012}
---------------------------------------

Potential participants were contacted via the ISTH database. Email invitations were sent to approximately 20 000 professionals (nonmembers and ISTH members from 24 selected countries). Invitations directed potential participants to a secure Web page to complete a screener.

Participants who categorized themselves as clinical physicians or as researchers had to spend at least 50% of their professional time caring for patients or in basic science or clinical research activities, respectively. For the fellow/student/resident category, potential participants had to have reached their fourth year of medical school or to be engaged in doctoral or postdoctoral studies. Industry representatives had to be currently working within the pharmaceutical, biotechnology, or medical devices industry and must have been doing so for at least 2 years. Nurses were excluded, as a separate needs assessment in their profession was being conducted simultaneously.[19](#rth212237-bib-0019){ref-type="ref"} Eligible participants had to be practicing in the targeted countries within each region (see Table [1](#rth212237-tbl-0001){ref-type="table"} legend). Countries were selected to reflect the membership distribution of ISTH and to represent a range of experiences while increasing the comparability of health systems and professional practices. All eligible participants were directed to an informed consent agreement, then either to the survey (phase 2) or to an availability form (phases 1 and 3).

###### 

Description of sample by region, occupation, and main practice area

                                                                                                                                              Asia & Pacific[b](#rth212237-note-0003){ref-type="fn"}   Eastern Europe[b](#rth212237-note-0003){ref-type="fn"}   Latin America[b](#rth212237-note-0003){ref-type="fn"}   Africa & Middle East[b](#rth212237-note-0003){ref-type="fn"}   North America[b](#rth212237-note-0003){ref-type="fn"}   Western Europe[b](#rth212237-note-0003){ref-type="fn"}   Total
  ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------
  Qualitative sample (phases 1 and 3) detailed by region and occupation --- n (% per region)                                                                                                                                                                                                                                                                                                                                                                                                            
  Clinical physicians                                                                                                                         2 (33%)                                                  2 (40%)                                                  6 (43%)                                                 5 (36%)                                                        5 (56%)                                                 4 (44%)                                                  24 (38%)
  Researchers (basic science and clinical)                                                                                                    2 (33%)                                                  2 (40%)                                                  7 (50%)                                                 6 (43%)                                                        3 (33%)                                                 3 (44%)                                                  23 (36%)
  Students/residents/postdoctoral fellows                                                                                                     2 (33%)                                                  1 (20%)                                                  1 (7%)                                                  3 (21%)                                                        1 (11%)                                                 2 (22%)                                                  10 (16%)
  Industry or other[a](#rth212237-note-0002){ref-type="fn"}                                                                                                                                            7 (11%)                                                                                                                                                                                                                                                                                          
  Total (qualitative)                                                                                                                         6 (9%)                                                   5 (8%)                                                   14 (22%)                                                14 (22%)                                                       9 (14%)                                                 9 (14%)                                                  64 (100%)
  Quantitative sample (phase 2) detailed by region and occupation --- n (% per region)                                                                                                                                                                                                                                                                                                                                                                                                                  
  Clinical physicians                                                                                                                         31 (66%)                                                 23 (77%)                                                 33 (60%)                                                26 (60%)                                                       39 (41%)                                                56 (51%)                                                 208 (51%)
  Clinical researchers                                                                                                                        2 (4%)                                                   5 (17%)                                                  10 (18%)                                                3 (7%)                                                         22 (23%)                                                16 (15%)                                                 58 (14%)
  Basic science researchers                                                                                                                   12 (26%)                                                 1 (3%)                                                   6 (11%)                                                 7 (16%)                                                        19 (20%)                                                19 (17%)                                                 64 (16%)
  Students/residents/postdoctoral fellows                                                                                                     2 (4%)                                                   1 (3%)                                                   6 (11%)                                                 7 (16%)                                                        14 (15%)                                                19 (17%)                                                 49 (12%)
  Industry or other[a](#rth212237-note-0002){ref-type="fn"}                                                                                                                                            25 (6%)                                                                                                                                                                                                                                                                                          
  Total (quantitative)                                                                                                                        47 (12%)                                                 30 (7%)                                                  55 (14%)                                                43 (11%)                                                       94 (23%)                                                110 (27%)                                                404 (100%)
  Quantitative sample detailed by region and main practice area for clinicians and clinical researchers --- n (% per region)                                                                                                                                                                                                                                                                                                                                                                            
  Thrombosis/clotting                                                                                                                         17 (52%)                                                 13 (46%)                                                 20 (47%)                                                10 (35%)                                                       28 (46%)                                                38 (53%)                                                 126 (47%)
  Hemophilia/bleeding                                                                                                                         6 (18%)                                                  8 (29%)                                                  6 (14%)                                                 9 (31%)                                                        10 (16%)                                                10 (14%)                                                 49 (18%)
  Equally in both areas                                                                                                                       10 (30%)                                                 7 (25%)                                                  17 (40%)                                                10 (35%)                                                       23 (38%)                                                24 (33%)                                                 91 (34%)
  Quantitative sample detailed by years of practice/research for clinicians and basic science and clinical researchers --- n (% per region)                                                                                                                                                                                                                                                                                                                                                             
  ≤10 y of practice/research                                                                                                                  18 (40%)                                                 7 (24%)                                                  15 (31%)                                                20 (56%)                                                       23 (29%)                                                39 (43%)                                                 122 (37%)
  11 y of practice/research or more                                                                                                           27 (60%)                                                 22 (76%)                                                 34 (69%)                                                16 (44%)                                                       57 (71%)                                                52 (57%)                                                 208 (63%)
  Sample detailed by ISTH membership status --- n (% per region)[c](#rth212237-note-0004){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                
  Member                                                                                                                                      39 (72%)                                                 25 (71%)                                                 36 (53%)                                                31 (54%)                                                       72 (69%)                                                68 (57%)                                                 287 [d](#rth212237-note-0005){ref-type="fn"}(62%)
  Nonmember                                                                                                                                   15 (28%)                                                 10 (29%)                                                 32 (47%)                                                26 (46%)                                                       32 (31%)                                                51 (43%)                                                 179 [d](#rth212237-note-0005){ref-type="fn"}(38%)

Includes laboratory managers and professionals in medical education. As many have worked internationally and have insights into multiple regions, participants were not categorized by region of practice.

Targeted countries by region: Asia & Pacific (Australia, China, Japan, New Zealand); Eastern Europe (Poland, Russia); Africa and Middle East (Egypt, Israel, Kenya, Nigeria, Saudi Arabia, South Africa, United Arab Emirates); North America (Canada, United States); Latin America (Argentina, Brazil, Mexico); Western Europe (Austria, France, Germany, Italy, Spain, United Kingdom).

Two participants did not answer.

Totals include industry representatives that are not categorized by region of practice.
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A purposive sampling strategy was used to increase the representativeness of the T&H community by targeting a variety of practice settings (community‐based, academic, specialized centers), countries, and years of experience. All subspecialties of clinicians or researchers in the field of T&H were included.

2.5. Qualitative analysis {#rth212237-sec-0013}
-------------------------

Qualitative data obtained from the semistructured interviews (phase 1) and discussion groups (phase 3) were analyzed using a directed qualitative content approach.[20](#rth212237-bib-0020){ref-type="ref"} Analysis began with the creation of a coding structure based on preidentified areas of exploration, with more themes added during the coding process. Multiple behavioral and educational researchers coded the transcripts using NVIVO software (QSR International, Cambridge, MA). Interviews were transcribed and coded until the coders unanimously determined that data saturation was reached. Data saturation is defined as a criterion for discontinuing data analysis when no new themes are identified that require creating new categories within the coding structure.[21](#rth212237-bib-0021){ref-type="ref"}, [22](#rth212237-bib-0022){ref-type="ref"} The most substantive themes that emerged were organized according to each participant\'s occupational subgroup.

2.6. Quantitative analysis {#rth212237-sec-0014}
--------------------------

Answers to the online survey (phase 2) were analyzed using SPSS software (version 22.0, IBM Corporation, Armonk, NY) and consisted of frequency tables and cross‐tabulations. Participants' answers were dichotomized to identify potential areas of improvement, similar to methods used in previous needs assessments.[23](#rth212237-bib-0023){ref-type="ref"}, [24](#rth212237-bib-0024){ref-type="ref"} More detail on this process is provided in Data S1.

Pearson chi‐squares with a 0.05 level of significance were used to identify differences between subgroups, based on the participant years of practice/research (ie, ≤10 vs. ≥11 years) and their main (but not exclusive) domain of practice (ie, thrombosis, bleeding, or both equally).

2.7. Final analysis and triangulation of data {#rth212237-sec-0015}
---------------------------------------------

Triangulation was performed by combining data gathered using qualitative and quantitative methods and from a variety of sources (clinicians, researchers, industry representatives, fellows/residents/students). Convergence and corroboration were sought as a way to minimize biases inherent in using only a single method[25](#rth212237-bib-0025){ref-type="ref"}, [26](#rth212237-bib-0026){ref-type="ref"} and to increase the validity and trustworthiness of the findings.[27](#rth212237-bib-0027){ref-type="ref"}, [28](#rth212237-bib-0028){ref-type="ref"}, [29](#rth212237-bib-0029){ref-type="ref"}, [30](#rth212237-bib-0030){ref-type="ref"}

2.8. Ethics {#rth212237-sec-0016}
-----------

This study received ethics approval from an independent ethics review board (VERITAS, Canada). Individual informed consent was obtained before participation in this study. Participants were entered into a draw for a chance to win registrations to the ISTH 2017 Congress and ISTH memberships.

3. RESULTS {#rth212237-sec-0017}
==========

Of the 1612 members of the T&H community who responded to the study invitations (response rate, 8%), 468 were eligible participants (232 clinicians, 145 basic science or clinical researchers, 59 fellows/residents/students, 32 industry representatives or others). Individual interviews (phase 1) were conducted with 45 participants, and online surveys (phase 2) were completed by 404 participants. Results from phases 1 and 2 were discussed with 19 participants in 3 live discussion groups (phase 3; Table [1](#rth212237-tbl-0001){ref-type="table"}).

Ten key themes that emerged from the triangulated analysis were identified as areas where the T&H community could benefit from additional support (Figure [1](#rth212237-fig-0001){ref-type="fig"}) and are detailed in the following sections.

![The 10 key themes that emerged from the triangulated analysis: areas where the T&H community could benefit from additional support](RTH2-3-626-g001){#rth212237-fig-0001}

3.1. Findings related to the diagnosis and testing of coagulation disorders {#rth212237-sec-0018}
---------------------------------------------------------------------------

### 3.1.1. Challenges in thrombosis risk assessment {#rth212237-sec-0019}

Conducting a clinical risk evaluation in thrombosis emerged as a challenge for participants with a clinical practice. As shown in Table [2](#rth212237-tbl-0002){ref-type="table"}, 28% of clinicians reported suboptimal knowledge, given their professional role, of the utilization of risk assessment models for venous thromboembolism (VTE). For subspecialties, 33% of clinicians practicing equally in thrombosis and bleeding disorders reported suboptimal knowledge in this area --- this proportion rose to 48% in the subgroup of clinicians practicing mainly (but not exclusively) in bleeding disorders.

###### 

Self‐reported level of knowledge and skills of clinicians practicing in the field of hemostatic disorders

  Survey questions                                                                                   Clinician\'s main (but not exclusive) domain of practice[a](#rth212237-note-0007){ref-type="fn"}   All clinicians   Significant differences by domain[d](#rth212237-note-0010){ref-type="fn"}   Years of practice[f](#rth212237-note-0012){ref-type="fn"}   Significant differences by years of practice[e](#rth212237-note-0011){ref-type="fn"} ^,^ [f](#rth212237-note-0012){ref-type="fn"}                                
  -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------- --------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ------------- -------------- ---------------------
  \% (n) of clinicians reported suboptimal knowledge about[b](#rth212237-note-0008){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                
  When, why, and how to use risk assessment models for VTE                                           16% (22/135)                                                                                       48% (25/52)      33% (35/107)                                                                28% (82/294)                                                ***P*** ** \< 0.001**                                                                                                               33% (30/91)   23% (41/175)   *P* = 0.10
  When, why, and how to apply Wells/Geneva score for DVT risk assessment                             27% (36/134)                                                                                       60% (31/52)      48% (51/107)                                                                40% (118/293)                                               ***P*** ** \< 0.001**                                                                                                               41% (37/90)   37% (64/175)   *P* = 0.05
  When, why, and how to order D‐dimer test                                                           19% (25/134)                                                                                       33% (17/52)      21% (22/107)                                                                22% (64/293)                                                *P* = 0.11                                                                                                                          24% (22/90)   19% (34/175)   *P* = 0.34
  When and why to order genetic testing in thrombosis patients                                       31% (42/134)                                                                                       29% (15/52)      32% (34/107)                                                                31% (91/293)                                                *P* = 0.93                                                                                                                          33% (30/90)   25% (43/175)   *P* = 0.13
  When and why to order genetic testing in bleeding disorders                                        59% (80/135)                                                                                       19% (10/52)      33% (35/107)                                                                43% (125/294)                                               ***P*** ** \< 0.001**                                                                                                               48% (44/91)   38% (66/175)   *P* = 0.10
  How to diagnose von Willebrand disease                                                             52% (70/134)                                                                                       6% (3/52)        28% (30/107)                                                                35% (103/293)                                               ***P*** ** \< 0.001**                                                                                                               38% (34/90)   32% (56/175)   *P* = 0.35
  Type of thromboprophylaxis treatment to use according to patient profile                           19% (25/134)                                                                                       40% (21/52)      34% (36/107)                                                                28% (82/293)                                                ***P*** ** = 0.003**                                                                                                                30% (27/90)   21% (37/175)   *P* = 0.11
  Use of anticoagulation in patients who have a history of bleeding episodes/bleeding disorders      25% (34/134)                                                                                       40% (21/52)      41% (44/107)                                                                34% (99/293)                                                ***P*** ** = 0.02**                                                                                                                 38% (34/90)   27% (48/175)   *P* = 0.08
  Timing to reinitiate antithrombotic/anticoagulant medication after hemorrhagic episode(s)          22% (29/134)                                                                                       42% (22/52)      36% (39/107)                                                                31% (90/293)                                                ***P*** ** = 0.01**                                                                                                                 36% (33/91)   23% (40/174)   ***P*** ** = 0.02**
  Treatment of bleeding episodes in hemophilia                                                       72% (96/134)                                                                                       8% (4/51)        41% (43/106)                                                                49% (143/291)                                               ***P*** ** \< 0.001**                                                                                                               57% (51/90)   45% (78/173)   *P* = 0.08
  Long‐term treatment to prevent bleeding episodes in hemophilia                                     75% (101/134)                                                                                      12% (6/52)       44% (47/107)                                                                53% (154/293)                                               ***P*** ** \< 0.001**                                                                                                               62% (56/90)   47% (82/175)   ***P*** ** = 0.02**
  Treatment options for von Willebrand disease                                                       65% (87/134)                                                                                       8% (4/52)        37% (39/106)                                                                45% (130/292)                                               ***P*** ** \< 0.001**                                                                                                               52% (47/90)   38% (66/174)   ***P*** ** = 0.03**
  \% (n) of clinicians reported suboptimal skills about:[c](#rth212237-note-0009){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Use and interpretation of Wells/Geneva score for diagnosing DVT                                    23% (30/129)                                                                                       51% (26/51)      46% (45/99)                                                                 36% (101/279)                                               ***P*** ** \< 0.001**                                                                                                               37% (33/90)   36% (63/173)   *P* = 0.98
  Use and interpretation of D‐dimer test                                                             18% (23/130)                                                                                       35% (18/51)      19% (19/98)                                                                 22% (60/279)                                                ***P*** ** = 0.003**                                                                                                                31% (28/90)   17% (29/173)   ***P*** ** = 0.01**
  Use and interpretation of international normalized ratio                                           12% (15/130)                                                                                       26% (13/51)      11% (11/100)                                                                14% (39/281)                                                ***P*** ** = 0.03**                                                                                                                 14% (13/90)   13% (22/175)   *P* = 0.67
  Use of results from genetic testing to guide treatment of thrombotic disorders                     35% (45/130)                                                                                       28% (14/51)      32% (32/99)                                                                 33% (91/280)                                                *P* = 0.65                                                                                                                          38% (34/90)   26% (46/174)   *P* = 0.06
  Use of results from genetic testing to guide treatment of bleeding disorders                       61% (79/130)                                                                                       18% (9/50)       41% (41/99)                                                                 46% (129/279)                                               ***P*** ** \< 0.001**                                                                                                               52% (46/88)   41% (71/175)   *P* = 0.07
  Diagnose von Willebrand disease                                                                    54% (70/129)                                                                                       12% (6/50)       32% (32/99)                                                                 38% (108/278)                                               ***P*** ** \< 0.001**                                                                                                               47% (42/89)   33% (57/173)   ***P*** ** = 0.02**
  Use of global assay test results to guide treatment                                                43% (54/127)                                                                                       44% (22/50)      31% (31/100)                                                                39% (107/277)                                               *P* = 0.14                                                                                                                          39% (35/90)   38% (65/171)   *P* = 0.89
  Determine treatment for VTE in cancer patients                                                     20% (26/130)                                                                                       51% (26/51)      34% (33/98)                                                                 31% (85/279)                                                ***P*** ** \< 0.001**                                                                                                               32% (28/89)   27% (47/174)   *P* = 0.45
  Adjust management of anticoagulation in patients who have a severe bleeding episode                26% (34/130)                                                                                       39% (20/51)      36% (35/97)                                                                 32% (89/278)                                                *P* = 0.14                                                                                                                          36% (32/88)   28% (48/174)   *P* = 0.15
  Adjust management of anticoagulation in patients who have a nonsevere bleeding episode             20% (26/130)                                                                                       41% (21/51)      31% (30/97)                                                                 28% (77/278)                                                ***P*** ** = 0.01**                                                                                                                 32% (28/88)   24% (42/174)   *P* = 0.19
  Decide type of prophylaxis treatment to use for bleeding episodes                                  39% (49/126)                                                                                       20% (10/51)      32% (32/99)                                                                 33% (91/276)                                                ***P*** ** = 0.05**                                                                                                                 41% (37/90)   27% (46/171)   ***P*** ** = 0.02**
  Decide treatment plan for von Willebrand disease                                                   62% (81/130)                                                                                       12% (6/51)       39% (38/98)                                                                 45% (125/279)                                               ***P*** ** \< 0.001**                                                                                                               54% (49/90)   38% (66/174)   ***P*** ** = 0.01**

DVT, deep vein thrombosis; VTE, venous thromboembolism.

Question: Which of these broad domains are your professional activities (practice, research, studies) more oriented towards?

Question: For each statement below, please select the number that best describes your level of knowledge, given your profession. Scale: 1 = Not acceptable given my profession; 3 = Acceptable but could be improved given my profession; 5 = Ideal given my profession.

Question: For each statement below, please rate your current level of skills in relation to what it should be, given your profession. Scale: 1 = Low; 3 = Acceptable; 5 = Optimal; 6 = Not applicable to my profession. Participants who answered 6 were not included in the frequency tables.

Pearson chi‐squares with a 0.05 level of significance were performed to identify differences between subgroups, according to the 3 domains of practice (ie thrombosis, bleeding, or both domains equally). Significant differences are shown in bold.

Pearson chi‐squares with a 0.05 level of significance were performed to identify differences between subgroups, according to years of practice (≤10 y of practice vs. ≥11 y of practice). Significant differences are shown in bold.

Student and residents having no actual years of practice were excluded from analysis by years of practice.
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When asked specifically about their level of knowledge of the Wells and Geneva scores, 40% of clinicians reported suboptimal knowledge. This proportion rose to 48% for clinicians practicing equally in thrombosis and bleeding disorders. In addition, a total of 36% of clinicians reported suboptimal skills, given their profession, interpreting the Wells and Geneva scores --- a proportion that rose to 46% in clinicians practicing equally in thrombosis and bleeding disorders. Skills interpreting the D‐dimer test and international normalized ratio results were reported as suboptimal by 22% and 14% of clinicians, respectively (Table [2](#rth212237-tbl-0002){ref-type="table"}). A greater proportion of clinicians with less experience reported suboptimal skills interpreting D‐dimer tests, compared to those with more experience (31% vs. 17%, *P* = 0.007).

### 3.1.2. Challenges with genetic testing in thrombosis and bleeding disorders {#rth212237-sec-0020}

The triangulated analysis identified genetic testing as an area where clinicians may benefit from educational interventions. Suboptimal knowledge of when to order genetic testing for thrombosis patients was reported by 31% of clinicians (Table [2](#rth212237-tbl-0002){ref-type="table"}), compared to 43% of clinicians when it concerns ordering genetic testing for a patient with a bleeding disorder.

Skills using genetic test results to guide treatment decisions were reported as suboptimal by 33% of clinicians for patients with a thrombotic condition and by 46% with a bleeding disorder (Table [2](#rth212237-tbl-0002){ref-type="table"}). A lack of clarity on best practices for genetic testing also emerged as a key theme during the interviews and discussion groups:"I think it affects a whole lot of decisions \[the absence of consensus around use of genetic testing\] with not just bleeding disorders. But there\'s no consensus. Guidelines \[vary\] from country to country, even within countries, even between the institutes in the same country there is not a consensus about guidelines when and why. Workshop participant \[\#11\]"

### 3.1.3. Challenges with diagnosis of von Willebrand disease {#rth212237-sec-0021}

Diagnosing von Willebrand disease (VWD) emerged as a challenging area for clinicians. A total of 35% of clinicians reported suboptimal knowledge of how to diagnose VWD (Table [2](#rth212237-tbl-0002){ref-type="table"}). Whereas only a small proportion of clinicians practicing mainly in bleeding disorders reported suboptimal knowledge (6%), more than half (52%) of clinicians who practice mainly in thrombosis disorders and 28% of clinicians practicing equally in both conditions reported suboptimal knowledge (*P* \< 0.001).

When asked about their skills in establishing a diagnosis of VWD, 38% of clinicians reported that their skills were suboptimal, with a higher proportion found in clinicians practicing mainly in thrombosis disorders (54%), compared to those practicing mainly in bleeding disorders (12%) or practicing equally in both (32%; *P* \< 0.001). The skill gap was higher in less experienced clinicians, compared to those with more experience (Table [2](#rth212237-tbl-0002){ref-type="table"}, 47% vs. 33%; *P* = 0.024).

### 3.1.4. Challenges with global assays in T&H disorders {#rth212237-sec-0022}

Integrating the results of global assays to inform treatment decisions was reported as a challenge. Among all clinicians, 39% reported suboptimal skills using these results to guide treatment (Table [2](#rth212237-tbl-0002){ref-type="table"}). In each of the 3 domains of practice, a similar proportion of clinicians reported suboptimal skills in this area.

3.2. Findings related to treatment decision making in T&H disorders {#rth212237-sec-0023}
-------------------------------------------------------------------

### 3.2.1. Challenges with anticoagulants in specific patients {#rth212237-sec-0024}

Challenges related to thromboprophylaxis regimens were also identified. Suboptimal knowledge of the type of thromboprophylaxis regimen to use, according to a patient profile, was reported by 28% of clinicians. In addition, 31% of clinicians reported suboptimal skills, given their role, in determining treatment for VTE in cancer patients (Table [2](#rth212237-tbl-0002){ref-type="table"}).

Patients with a thrombotic disorder in addition to a bleeding history also represented a treatment challenge. Suboptimal knowledge of the use of anticoagulant medication in patients with a history of bleeding episodes was reported by 34% of clinicians. This gap was higher among clinicians practicing mainly in bleeding disorders (40%) and those practicing equally in both domains (41%; *P* = 0.020). Specifically, 31% of clinicians reported suboptimal knowledge of the correct timing to reinitiate anticoagulants in patients that have had a hemorrhagic episode. A higher proportion of less experienced clinicians reported having a knowledge gap in this area, as compared to more experienced clinicians (36% vs. 23%; *P* = 0.022). Skills in adjusting anticoagulant medication were reported as suboptimal by 32% of clinicians for patients who have had a *severe* bleeding episode and by 28% for patients who have had a *nonsevere* bleeding episode (Table [2](#rth212237-tbl-0002){ref-type="table"}).

### 3.2.2. Challenges with preventive treatments in bleeding disorders {#rth212237-sec-0025}

Suboptimal knowledge of treatment for bleeding episodes in people with hemophilia was reported by nearly half of participants (49%). This knowledge gap was self‐reported by a majority (72%) of clinicians mainly practicing in thrombosis and by 41% of participants practicing in both areas equally (*P* \< 0.001). Suboptimal knowledge of long‐term prevention of bleeding episodes in hemophilia patients was also self‐reported by clinicians practicing in both domains equally (44%) and clinicians practicing mainly in thrombosis (75%; *P* \< 0.001). This proportion was significantly higher among less experienced clinicians, as compared to those with more experience (62% vs. 47%; *P* = 0.018).

One third (33%) of clinicians reported suboptimal skills in deciding the type of prophylaxis treatment to use to prevent bleeding episodes. This proportion rose to 41% among less experienced clinicians, in contrast to 27% of more experienced clinicians (*P* = 0.019).

### 3.2.3. Challenges around treatment of VWD {#rth212237-sec-0026}

Knowledge of treatment options for VWD was reported as suboptimal by 65% of clinicians practicing mainly in thrombosis and 37% practicing equally in both domains (*P* \< 0.001). A significantly higher proportion of less experienced clinicians than those with more experience also reported suboptimal knowledge of the treatment options for VWD (52% vs. 38%; *P* = 0.026).

A similar situation was found in the self‐reported ability to decide on a treatment plan for patients with VWD, as 62% of clinicians practicing mainly in thrombosis and 39% practicing in both domains equally reported suboptimal skills in this area (*P* \< 0.001), as did a higher proportion of less experienced than more experienced clinicians (54% vs. 38%, *P* = 0.010). Less experienced clinicians lacking confidence was a recurrent and emerging qualitative theme:"I think von Willebrand disease is hard. It\'s really hard to make a plan for a patient and if you talk to one doctor and he will tell you, "Oh, I will do this," and then you talk to somebody else and he will say, "I will do that." \[...\] I don\'t know if I\'m 100% confident about how to approach a von Willebrand patient \[...\], because I don\'t think that there\'s just one answer on that. And I don\'t have enough years of practicing. Workshop participant \[\#25\]"

3.3. Findings related to research in the T&H field {#rth212237-sec-0027}
--------------------------------------------------

### 3.3.1. Challenges around collaboration with and among researchers {#rth212237-sec-0028}

Collaboration in the research community was among the reported challenges. Over half of researchers (52%) reported that collaborating with other researchers not directly in their area of expertise was difficult (Table [3](#rth212237-tbl-0003){ref-type="table"}). Specifically, 39% of researchers perceived that it was difficult to collaborate with clinical researchers. From a list of 12 barriers to conducting research, a "lack of communication between basic science and clinical researchers" was the item most often selected (Figure [2](#rth212237-fig-0002){ref-type="fig"}).

###### 

Perceptions of T&H researchers

  Survey questions                                                                                                            Researchers whose activities are more oriented toward...   All researchers                 
  --------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------- ------------- --------------
  \% (n) of researchers that perceived the following as difficult or very difficult[a](#rth212237-note-0014){ref-type="fn"}                                                                                              
  Collaborating with other researchers *not* directly in my area of expertise                                                 47% (29/62)                                                55% (11/20)       57% (30/53)   52% (70/135)
  Collaborating with clinical researchers                                                                                     32% (20/63)                                                43% (9/21)        45% (26/58)   39% (55/142)
  Collecting data from patients in the context of noninterventional studies                                                   36% (20/55)                                                68% (13/19)       49% (22/45)   46% (55/119)
  Collecting data from patients in the context of interventional studies                                                      35% (18/52)                                                43% (6/14)        49% (17/35)   41%(41/101)

  General facets of research                                                                                                                                  \% (n) selected that should have *more* importance   \% (n) selected that should have *less* importance
  ----------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  \% (n) of researchers that selected these aspects as ones that should be given *more* importance in the T&H field[b](#rth212237-note-0015){ref-type="fn"}                                                        
  Creation of networking opportunities for researchers                                                                                                        58% (62/107)                                         5% (5/107)
  Promoting and stimulating T&H basic science research                                                                                                        67% (72/108)                                         6% (6/108)
  Support for large multisite, multicountry studies                                                                                                           49% (52/107)                                         16% (17/107)

  Research topics                                                                                                                                            \% (n) selected "should have *more* importance"   \% (n) selected "should have *less* importance"
  ---------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  \% (n) of researchers that selected these topics as ones that should be given *more* importance in the T&H field[b](#rth212237-note-0015){ref-type="fn"}                                                     
  Link to and relation between immune response, inflammation, and coagulation                                                                                69% (74/108)                                      4% (4/108)
  Link between cancer and thrombosis                                                                                                                         63% (69/109)                                      5% (5/109)
  Support the development of personalized medicine in the thrombosis and hemostasis field                                                                    61% (66/108)                                      7% (7/108)
  Contributions of the clotting and fibrinolytic systems to nonhemostatic processes in general                                                               50% (53/107)                                      9% (10/107)
  Role of platelet physiology in nonhemostatic systems                                                                                                       46% (50/109)                                      13% (14/109)
  Development of animal models for basic science research                                                                                                    42% (45/108)                                      19% (21/108)
  Novel causes (including genetic) of bleeding disorders                                                                                                     41% (44/108)                                      12% (13/108)
  Role of the coagulation system in arterial thrombosis                                                                                                      36% (39/108)                                      7% (7108)
  Engineering of less immunogenic factor concentrates                                                                                                        27% (29/106)                                      23% (24/106)
  Relation between neutrophil extracellular trap, the contact pathway, and thrombosis                                                                        25% (26/108)                                      10% (11/108)
  Role of platelet polyphosphates in hemostasis and thrombosis                                                                                               23% (25/108)                                      18% (19/108)
  Immunological basis of hemophilia inhibitors                                                                                                               23% (24/104)                                      17% (18/104)
  Immunological basis of immune thrombocytopenia                                                                                                             12% (13/105)                                      24% (25/105)

T&H, thrombosis and hemostasis.

Question: Please rate your current level of difficulty in relation to these research tasks. Scale: 1 = Very difficult; 4 = Very easy; 5 = Not relevant to me. Participants who selected 5 were not included in the table.

To the best of your knowledge, do you think these research aspects or topics should be given: 1. More importance; 2. The same importance; or 3. Less importance by the research community in the field of thrombosis and hemostasis?

John Wiley & Sons, Ltd

![Barriers to conducting research in T&H field](RTH2-3-626-g002){#rth212237-fig-0002}

A majority of basic science researchers (58%) reported that the creation of networking opportunities for T&H researchers should be given more importance. "Lack of communication between clinicians and clinical researchers" was among the top 3 barriers to optimal care most frequently selected by clinicians (Figure [3](#rth212237-fig-0003){ref-type="fig"}). This barrier was more often selected by clinicians practicing mainly in thrombosis (38%) compared to those practicing mainly in bleeding disorders (15%) or equally in both domains (25%).

![Barriers to providing optimal care](RTH2-3-626-g003){#rth212237-fig-0003}

### 3.3.2. Challenges in collaboration between teams to collect data from human subjects {#rth212237-sec-0029}

Collecting human data in T&H research was reported as challenging. Nearly half of researchers (46%) reported that data collection from patients was "difficult" or "very difficult" in the context of noninterventional studies; in the context of interventional studies, 41% reported this as difficult.

A specific challenging facet of gathering human data was related to the communication and collaboration needed between physicians and nurses to collect human blood samples:"The main problem with such studies is that doctors just get to collect blood for the point of the study, and the biggest challenge is to make them collect blood in time, in those points that we study. Clinical researcher, Russia \[\#43\]"

### 3.3.3. Perception that basic science research in the field of T&H is not adequately promoted {#rth212237-sec-0030}

A majority of researchers (67%) indicated that promoting and stimulating basic science research should be given more importance by the research community in the field of T&H. Specifically, better support of multisite and multicountry studies should be given more importance, according to 49% of researchers.

When asked which topics should be better promoted among the research community in T&H, researchers cited 2 topics: the relationship between immune response, inflammation, and coagulation (69%); and the link between cancer and thrombosis (63%) (see Table [3](#rth212237-tbl-0003){ref-type="table"} for details).

4. DISCUSSION {#rth212237-sec-0031}
=============

This mixed‐methods study aimed to identify areas where the T&H community faced challenges and therefore could benefit from the support of a specialty society. Three broad challenge areas emerged: diagnosis and testing of coagulation disorders, treatment decision making, and researcher‐specific challenges. Study results indicated that within these core areas, clinicians had a suboptimal level of skills and knowledge of issues outside their specialty area; clinicians with less experience reported greater challenges; and collaboration between stakeholders in T&H was challenging across subspecialties and professional roles.

This study provides a platform to discuss the consequences of these core challenges on health care systems and to consider the contextual factors that may have affected the findings. The present discussion articulates the potential root causes and implications of these findings. Some of the study findings underscore the need for further educational offerings on topics that are consistent with the required competencies of clinicians practicing in T&H, as reported in the clinical core curriculum developed by the ISTH.[31](#rth212237-bib-0031){ref-type="ref"}

Participants who work primarily in bleeding disorders reported challenges when conducting risk assessments for VTE and when deciding when to order (and how to interpret) genetic tests. Conversely, those who specialize in thrombosis experienced challenges diagnosing and planning treatments for patients with VWD. Participants in either specialization generally reported greater skill and knowledge levels when operating within their main area of practice, compared to those who practice in both areas, which is not unexpected. Making decisions regarding the treatment and prevention of bleeding episodes in hemophilia patients was challenging for nearly half of those working equally in T&H, and in an even greater proportion of those who mainly (but not exclusively) work in the field of thrombosis.

The gaps in knowledge of certain issues related to T&H are concerning. For instance, when a thrombosis risk assessment is not performed properly, VTE diagnosis can be missed, and diagnostic imaging is likely to be overused. A lack of knowledge of how to perform a risk assessment, or which thromboprophylaxis method to use according to a patient\'s profile, may place patients at risk for VTE or a bleeding episode if thromboprophylaxis is inappropriately prescribed. The observed gaps relating to the diagnosis and treatment of VWD suggest how underreporting, and a lack of skills to treat the disease could put the patient at risk of bleeding. The reporting of suboptimal skills using results of global assays to guide treatment may, however, in part reflect participants' perception that these assays lack definition in current clinical management of bleeding and clotting disorders due to their inherent limitations rather than the individual\'s lack of knowledge. Nevertheless, since these assays are increasingly used,[32](#rth212237-bib-0032){ref-type="ref"} education is required to clarify their role and define their limitations.

This study found that clinicians with \<10 years of experience reported challenges in interpreting test results, both for diagnosis purposes and when making treatment decisions for bleeding disorders, especially VWD. As was anticipated, clinicians with more practice in the field of thrombosis had less confidence in diagnosis and treatment of patients with hemorrhagic disorders and vice versa. These variables could help inform the design of educational and professional development programs.

Researchers described how communication and collaboration posed a challenge, whether with researchers in‐ or outside their subarea of expertise, with clinicians, or in collaborations with industry. These difficulties are perceived as primary barriers to research and may hinder the potential benefits of collaboration. This finding parallels a recent needs assessment of knowledge and skills among clinical researchers in thrombosis, who reported gaps in their skills related to teamwork, time management, and leadership, in addition to confidence gaps pertaining to knowledge translation and grant writing and review.[33](#rth212237-bib-0033){ref-type="ref"} Interestingly, these gaps were not observed in our study. This difference could be explained by the fact that this Canadian study was conducted with research faculty only, whereas our study involved a broader research community.

Researchers also indicated that there is a need for the ISTH and the T&H community to better externally promote and support basic science research and to increase awareness of the crucial role basic science research plays in driving new treatments and clinical practices.[34](#rth212237-bib-0034){ref-type="ref"}

4.1. Study limitations {#rth212237-sec-0032}
----------------------

Although this study identified key gaps in knowledge, skills, and attitude in T&H, future studies explaining the exact root causes of these gaps are warranted, especially at a local level. Data collected were based on self‐reports rather than objective observational data. The sample size was appropriate for this type of exploratory mixed‐methods study; however, given that the total sample size was distributed across several regions and divided between clinicians and researchers, subgroup findings should be interpreted as indicators only. Perception of patients were not included in this initiative.

There is a risk of selection bias regarding both the participants in the different study phases and the initial choice of general areas to be presented in the interviews.

This study included but did not distinguish between participants from developed and developing countries, which poses limitations on how the findings should be generalized. In all instances, responses likely varied depending on the participants' access to research facilities or funding, their individual professional role, and the presence or absence of collaboration opportunities or an expert consensus on best practices.

Illustrative quotes from workshop participants were reported, but the exact profession and country of practice were not due to difficulties distinguishing the identity of a speaker from a recorded group discussion.

4.2. Conclusions {#rth212237-sec-0033}
----------------

Educational interventions should be designed to broaden the knowledge and skills of clinicians across the entire field of T&H, with emphasis on those practicing equally in both domains, as a way to provide consistent patient care. These educational offerings should focus on the 7 key themes that emerged from the triangulated analysis as areas of priorities around the diagnosis and testing of coagulation disorders and in relation to treatment decision making in T&H disorders. Findings related to research in T&H demonstrate a need for enhanced networking and collaboration opportunities, as well as increased promotion of basic science research.
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